Cover Image
市場調查報告書

Teijin Pharma Limited:產品平台分析

Teijin Pharma Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 271850
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Teijin Pharma Limited:產品平台分析 Teijin Pharma Limited - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 45 Pages
簡介

身為醫療設備廠商的Teijin Pharma Limited專門製造、銷售針對骨·關節疾病,呼吸系統疾病,代謝·循環系統疾病等治療所用的醫療設備。該公司的產品有治療骨質疏鬆症藥,氣喘的吸入皮質類固醇藥,細微支氣管狹窄治療藥,高尿酸血症治療劑,代謝性障礙治療藥等。同時也製造為了擴大咽峽炎/心肌梗塞患者的冠狀動脈所的經皮貼片製劑。

本報告提供Teijin Pharma Limited的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Teijin Pharma Limited的基本資料

  • Teijin Pharma Limited概要
  • 主要資訊
  • 企業資料

Teijin Pharma Limited:R&D概要

  • 主要的治療範圍

Teijin Pharma Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Teijin Pharma Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Teijin Pharma Limited:藥物簡介

  • febuxostat
  • immune globulin (human)
  • abaloparatide
  • KTP-001
  • lanreotide acetate
  • ADC-3680
  • ambroxol
  • TMG-123
  • Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis
  • Small Molecules to Target ROR gamma for Autoimmune Diseases

Teijin Pharma Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Teijin Pharma Limited:最近的開發平台趨勢

Teijin Pharma Limited:暫停中的計劃

Teijin Pharma Limited:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • NTC-801
    • taspoglutide

Teijin Pharma Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07310CDB

Summary

Global Markets Direct's, 'Teijin Pharma Limited - Product Pipeline Review - 2015', provides an overview of the Teijin Pharma Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Teijin Pharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Teijin Pharma Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Teijin Pharma Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Teijin Pharma Limited's pipeline products

Reasons to buy

  • Evaluate Teijin Pharma Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Teijin Pharma Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Teijin Pharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Teijin Pharma Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Teijin Pharma Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Teijin Pharma Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Teijin Pharma Limited Snapshot
    • Teijin Pharma Limited Overview
    • Key Information
    • Key Facts
  • Teijin Pharma Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Teijin Pharma Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Teijin Pharma Limited - Pipeline Products Glance
    • Teijin Pharma Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Teijin Pharma Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Teijin Pharma Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Teijin Pharma Limited - Drug Profiles
    • immune globulin (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • abaloparatide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADC-3680
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KTP-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lanreotide acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TMG-123
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target ROR gamma for Autoimmune Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Teijin Pharma Limited - Pipeline Analysis
    • Teijin Pharma Limited - Pipeline Products by Target
    • Teijin Pharma Limited - Pipeline Products by Route of Administration
    • Teijin Pharma Limited - Pipeline Products by Molecule Type
    • Teijin Pharma Limited - Pipeline Products by Mechanism of Action
  • Teijin Pharma Limited - Recent Pipeline Updates
  • Teijin Pharma Limited - Dormant Projects
  • Teijin Pharma Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • NTC-801
      • taspoglutide
  • Teijin Pharma Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Teijin Pharma Limited, Key Information
  • Teijin Pharma Limited, Key Facts
  • Teijin Pharma Limited - Pipeline by Indication, 2015
  • Teijin Pharma Limited - Pipeline by Stage of Development, 2015
  • Teijin Pharma Limited - Monotherapy Products in Pipeline, 2015
  • Teijin Pharma Limited - Partnered Products in Pipeline, 2015
  • Teijin Pharma Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Teijin Pharma Limited - Out-Licensed Products in Pipeline, 2015
  • Teijin Pharma Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Teijin Pharma Limited - Phase III, 2015
  • Teijin Pharma Limited - Phase II, 2015
  • Teijin Pharma Limited - Phase I, 2015
  • Teijin Pharma Limited - Preclinical, 2015
  • Teijin Pharma Limited - Discovery, 2015
  • Teijin Pharma Limited - Pipeline by Target, 2015
  • Teijin Pharma Limited - Pipeline by Route of Administration, 2015
  • Teijin Pharma Limited - Pipeline by Molecule Type, 2015
  • Teijin Pharma Limited - Pipeline Products by Mechanism of Action, 2015
  • Teijin Pharma Limited - Recent Pipeline Updates, 2015
  • Teijin Pharma Limited - Dormant Developmental Projects,2015
  • Teijin Pharma Limited - Discontinued Pipeline Products, 2015
  • Teijin Pharma Limited, Other Locations
  • Teijin Pharma Limited, Subsidiaries

List of Figures

  • Teijin Pharma Limited - Pipeline by Top 10 Indication, 2015
  • Teijin Pharma Limited - Pipeline by Stage of Development, 2015
  • Teijin Pharma Limited - Monotherapy Products in Pipeline, 2015
  • Teijin Pharma Limited - Partnered Products in Pipeline, 2015
  • Teijin Pharma Limited - Pipeline by Top 10 Target, 2015
  • Teijin Pharma Limited - Pipeline by Top 10 Route of Administration, 2015
  • Teijin Pharma Limited - Pipeline by Top 10 Molecule Type, 2015
  • Teijin Pharma Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top